Several injections of Ofatumumab are effective

Ofatumumab is a drug used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. The dosage and duration of treatment of ofatumumab may vary for different diseases. Ofatumumab is administered by intravenous infusion, usually initially over about 6 hours. Infusion times may be shortened depending on the patient's tolerance to ofatumumab.

Ofatumumab may start working immediately, but it may take several months to see changes in cancer progression, trials studying ofatumumab looked at progression-free survival and reported. In patients treated with ofatumumab plus chlorambucil, their previously untreated CLL did not worsen for a median duration of 22 months, with 82% of patients having a response, including 12% seeing their cancer disappear. These responses lasted an average of 22 months;In people whose CLL disease relapsed with ofatumumab plus fludarabine plus cyclophosphamide, for an average of 29 months, the disease did not worsen and 84% of patients responded, including 29% who lost their cancer. Patients lived an average of 56 months.

The original drug of ofatumumab has been launched in China and has also been included in medical insurance. Only patients who meet the indications can be reimbursed. The price is around tens of thousands of yuan, and domestic purchase channels are relatively difficult. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.